Literature DB >> 9367403

Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.

S Rafati1, S Couty-Jouve, M H Alimohammadian, J A Louis.   

Abstract

Soluble Leishmania antigen (SLA) from both developmental stages of L. major (L. major MRHO/IR/75/ER) were prepared. Three and five subfractions of SLA from amastigote and promastigote were obtained by fast protein liquid chromatography (FPLC), respectively. Biochemical analyses and comparison of amastigote and promastigote SLA were done. The biochemical analyses revealed that the first fraction of L. major amastigote possesses a distinct band on its electrophoretic mobility pattern corresponding to a position of 24 kD, and it has enzymatic activity with characteristics of a cysteine proteinase. The isolated fractions of amastigote were tested for induction of proliferation, interferon-gamma (IFN-gamma) and IL-4 production in cultures of peripheral blood mononuclear cells (PBMC) from individuals who had recovered and also chronic patients of cutaneous leishmaniasis caused by L. major. The cells of recovered individuals compared with chronic cases proliferated profoundly in response to the first fraction of amastigote SLA. In all recovered individuals, the IFN-gamma, but not IL-4, was secreted in response to stimulation with the first fraction of amastigote SLA. In chronic cutaneous leishmaniasis, IFN-gamma was infrequently observed in response to stimulation by all three fractions of amastigote SLA, but secretion of IL-4 was observed. These data indicate that first fraction of amastigote SLA is a strong inducer of primed human immune response to L. major, and may have a protective function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367403      PMCID: PMC2265498          DOI: 10.1111/j.1365-2249.1997.tb08318.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Cysteine proteinases of parasitic protozoa.

Authors:  M J North; J C Mottram; G H Coombs
Journal:  Parasitol Today       Date:  1990-08

2.  Leishmania major and L. donovani: a method for rapid purification of amastigotes.

Authors:  T A Glaser; S J Wells; T W Spithill; J M Pettitt; D C Humphris; A J Mukkada
Journal:  Exp Parasitol       Date:  1990-10       Impact factor: 2.011

Review 3.  Development of vaccines against leishmaniasis.

Authors:  F Modabber
Journal:  Scand J Infect Dis Suppl       Date:  1990

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

6.  Leishmania mexicana: amastigote hydrolases in unusual lysosomes.

Authors:  M F Pupkis; L Tetley; G H Coombs
Journal:  Exp Parasitol       Date:  1986-08       Impact factor: 2.011

7.  Inhibition of Leishmania amastigote growth by antipain and leupeptin.

Authors:  G H Coombs; J Baxter
Journal:  Ann Trop Med Parasitol       Date:  1984-02

8.  Axenic culture of Leishmania amastigotes.

Authors:  P A Bates
Journal:  Parasitol Today       Date:  1993-04

9.  A developmentally regulated cysteine proteinase gene of Leishmania mexicana.

Authors:  J C Mottram; C D Robertson; G H Coombs; J D Barry
Journal:  Mol Microbiol       Date:  1992-07       Impact factor: 3.501

10.  Proteinases of Leishmania mexicana amastigotes and promastigotes: analysis by gel electrophoresis.

Authors:  M J North; G H Coombs
Journal:  Mol Biochem Parasitol       Date:  1981-09       Impact factor: 1.759

View more
  7 in total

1.  Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.

Authors:  A Sassi; H Louzir; A Ben Salah; M Mokni; A Ben Osman; K Dellagi
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity.

Authors:  Alicia Ponte-Sucre; Radim Vicik; Martina Schultheis; Tanja Schirmeister; Heidrun Moll
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection.

Authors:  S Ajdary; M H Alimohammadian; M B Eslami; K Kemp; A Kharazmi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.

Authors:  S Rafati; A A Baba; M Bakhshayesh; M Vafa
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.

Authors:  Abebe Genetu Bayih; Nada S Daifalla; Lashitew Gedamu
Journal:  PLoS Negl Trop Dis       Date:  2014-12-11

Review 6.  A Historic Review of the Role of CD4+ T-Cell Subsets in Development of the Immune Responses against Cutaneous and Visceral Leishmaniases

Authors:  Mohammad Hossein Alimohmmadian; Soheila Ajdary; Fariborz Bahrami
Journal:  Iran Biomed J       Date:  2022-03-01

7.  Computational analysis of cysteine proteases (Clan CA, Family Cl) of Leishmania major to find potential epitopic regions.

Authors:  Babak Saffari; Hassan Mohabatkar
Journal:  Genomics Proteomics Bioinformatics       Date:  2009-09       Impact factor: 7.691

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.